Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
rofecoxib · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| lumiracoxib | DEVICE | 400 mg once daily, oral over 6 weeks |
| rofecoxib | DRUG | 25 mg, oral, daily over 6 weeks |
Inclusion Criteria: * Age \>=50 years old * Primary osteoarthritis in hip, hand, knee or spine for at least 3 month * Pain in the target joint of moderate intensity * Written informed consent Exclusion Criteria: * Secondary osteoarthritis * Active upper gastro intestinal tract ulceration * Inflam...
Rofecoxib is a small molecule being developed for the treatment of osteoarthritis, a musculoskeletal condition. It is currently in Phase 3 clinical development and is being studied in patients with osteoarthritis.
Rofecoxib is being developed by Novartis AG, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The drug is currently in Phase 3 clinical trials for osteoarthritis.
Rofecoxib is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 3 clinical trial for osteoarthritis has been completed.
Rofecoxib has been studied in a Phase 3 clinical trial with the identifier NCT00637949, titled 'Safety of Lumiracoxib in Patients With Osteoarthritis'. This trial enrolled 309 participants and has been completed.
Rofecoxib is also known as lumiracoxib. The clinical trial NCT00637949, which studied the drug in patients with osteoarthritis, uses the name lumiracoxib in its title, confirming that the two names refer to the same drug.